Updated Recommendations for the Bioanalysis of Antibody–Drug Conjugates (ADC) from the ADC working group of the AAPS Bioanalytical Community
Authors:
- Jim X. ShenJSJim X. Shen
- Robert DodgeRDRobert Dodge
- Shoshana ObersteinSOShoshana Oberstein
- Jennifer CunliffeJCJennifer Cunliffe
- Varun RamaniVRVarun Ramani
- Soumya Mohana SundaramSSSoumya Mohana Sundaram
- Ines C. SantosISInes C. Santos
- Chongwoo YuCYChongwoo Yu
- Sanjay L. DholakiyaSDSanjay L. Dholakiya
- Seema KumarSKSeema Kumar
- Xiaohui Sophia XuXXXiaohui Sophia Xu
- Sasha FraserSFSasha Fraser
Open Access
- 1 July 2026
- journal article
- review article
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (4)
Abstract
Antibody–drug conjugates (ADCs) represent a rapidly evolving therapeutic modality, combining the selective targeting of monoclonal antibodies with highly potent small molecule payloads. Their inherent structural complexity demands a sophisticated and multi-faceted bioanalytical approach spanning preclinical discovery through late-stage clinical development. This white paper, developed by the ADC Working Group of the AAPS bioanalytical community, comprising over 100 members from industry, contract research organizations (CROs), and regulatory agencies, provides updated recommendations for ADC bioanalysis. Building upon the foundational 2013 AAPS position paper and recent publications governing regulatory frameworks on PK considerations, this work addresses advances in bioanalytical quantitation strategies for total antibody (tAb), conjugated ADC, free (unconjugated) payload, and drug-to antibody ratio (DAR); novel immunogenicity assessment considerations; soluble target interference; critical reagent lifecycle management; payload-specific stability requirements; cross-validation strategies; and regulatory considerations. The recommendations presented herein reflect over a decade of scientific progress and are designed to serve as a comprehensive, empirically validated, and industry aligned bioanalytical framework for contemporary ADC drug development.Keywords
This publication has 48 references indexed in Scilit:
- Bioanalysis Special Focus Issue on Antibody–Drug ConjugatesBioanalysis, 2013
- Bioanalysis of Antibody–Drug Conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group Position PaperBioanalysis, 2013
- Liquid chromatography coupled with tandem mass spectrometry for the bioanalysis of proteins in drug development: Practical considerations in assay development and validationJournal of Chromatography A, 2013
- A universal surrogate peptide to enable LC‐MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc‐fusion protein drug candidates in pre‐clinical animal studiesBiomedical Chromatography, 2012
- Challenges in Developing Bioanalytical Assays for Characterization of Antibody–Drug ConjugatesBioanalysis, 2011
- The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometryJournal of Immunological Methods, 2009
- Orthogonal extraction/chromatography and UPLC, two powerful new techniques for bioanalytical quantitation of desloratadine and 3-hydroxydesloratadine at 25 pg/mLJournal of Pharmaceutical and Biomedical Analysis, 2006
- In vivoDrug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin ImmunoconjugateClinical Cancer Research, 2005
- Secondary mAb−vcMMAE Conjugates Are Highly Sensitive Reporters of Antibody Internalization via the Lysosome PathwayBioconjugate Chemistry, 2004
- The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 1998